Hydroxychloroquine, an antimalarial drug dubbed a “gift from God” by US President Donald Trump for its potential ability to fight the new coronavirus, was found to be no more effective than standard treatment in a small Chinese study.
The paper, which was published in the Journal of Zhejiang University on March 6, looked at 30 COVID-19 patients, half of whom received the medicine.
After seven days, 13 of the patients who were on the drug tested negative, compared to 14 people who weren’t on it.
One of the patients on it went on to develop severe illness, while the median time taken for the individuals to recover was similar in both groups.
The sample size is considered too small to be statistically significant.
But a similar number of patients were examined in a recent French study that found the same drug to be highly effective at fighting the infection, especially when taken in combination with the antibiotic azithromycin.
That triggered heightened global interest in hydroxychloroquine, and a related compound called chloroquine, which are synthetic forms of quinine and have for decades been used to treat malaria, as well as rheumatoid arthritis and lupus.
President Donald Trump last week announced his administration was working with pharmaceutical companies to expand access to the medicines so that more doctors can prescribe them “off label” — meaning not for their original intended use.
Trump has said they could be a “gift from God” and a “game changer,” even as many scientists have cautioned against overhyping unproven medicines before large scale clinical trials are carried out.
Such experiments are considered the gold standard in the field, last months or years and involve thousands of patients, often from around the world.
Patients are assigned at random to either receive the drug under investigation or a placebo, and the studies are “blinded” meaning the participants and their doctors are unaware which group they are in, to further reduce bias.
New York state, now the US epicenter of the pandemic with more than 30,000 cases and almost 200 deaths, began such a trial on Tuesday.
A man in Arizona, meanwhile, died this week after he ingested a non-medical form of chloroquine used to fight parasites in aquariums.
His wife, who also took the substance and was hospitalized, reported they had heard Trump talk about the benefits of the medicine and decided to try it.
© 2020 AFP
Investigative journalist who’s been covering Trump for 35 years explains why you need to take Mary’s Trump’s book seriously
Mary Trump’s book deserves your close attention because the president’s niece has two advantages that the small band of us who have studied Trump closely over the years do not.
First, she’s family. No one knows you like your family. Your family knows how you behaved at crucial moments when life changing events occur -- births, deaths, divorces, medical emergencies and weddings -- as well as mundane events like Saturday breakfast
‘When the Supreme Court hands down the decision about Trump’s taxes – read page 185’: Maddow says of new book
The country is awaiting the ruling on whether President Donald Trump must disclose his financial information as part of New York investigations into fraud. In her Tuesday show, MSNBC's Rachel Maddow explained that she has been through Trump's niece's book from cover to cover and encouraged people to look at page 185, where Mary Trump details how she ended up speaking to the New York Times about the financial records of Trump and his father.
According to the story, Times reporter Suzanne Craig appeared at Mary Trump's door asking about the information. Mary explained that she didn't have any of the documents, but Craig suggested that their lawyer might.
Wall Street is abandoning Trump as his re-election bid looks doomed: report
President Donald Trump has been sinking in the polls for weeks, as a combination of a deadly pandemic, freefalling economy, and nationwide racial unrest has started to undermine even some of his steadfast supporters' confidence in his ability to lead the nation. But for a long time, the financial industry and betting markets at least were more bullish on the president's ability to pull off another win.